EMBL Ventures backs Allecra Therapeutics' series B round that will support a phase 2 clinical trial for a therapy aimed at drug-resistant bacteria.
Allecra Therapeutics, a Germany and France-based biopharmaceutical company, has closed a €22m ($22m) series B round featuring EMBL Ventures, the investment arm of research institute European Molecular Biology Laboratory.
The round also included Delos Capital, which acted as lead investor, Forbion Capital Partners, Edmond de Rothschild Investment Partners, assorted private investor and Allecra co-founder Nicholas Benedict.
Founded in 2013, Allecra Therapeutics is working on antibiotic combinations to treat drug-resistant gram-negative bacterial infections.
The company is the result of a strategic partnership between pharmaceutical firm Orchid Chemicals and Pharmaceuticals, Forbion, Rothschild and the company founders.
Allecra will use the cash injection to fund a phase 2 clinical trial for its drug candidate AAI202.
In 2013, Allecra raised €15m in series A capital from EMBL Ventures, Rothschild and Forbion.
